Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs

Authors: Stephanie Seneff 1Greg Nigh 2Anthony M Kyriakopoulos 3Peter A McCullough 4

PMID: 35436552 PMCID: PMC9012513 DOI: 10.1016/j.fct.2022.113008


The mRNA SARS-CoV-2 vaccines were brought to market in response to the public health crises of Covid-19. The utilization of mRNA vaccines in the context of infectious disease has no precedent. The many alterations in the vaccine mRNA hide the mRNA from cellular defenses and promote a longer biological half-life and high production of spike protein. However, the immune response to the vaccine is very different from that to a SARS-CoV-2 infection. In this paper, we present evidence that vaccination induces a profound impairment in type I interferon signaling, which has diverse adverse consequences to human health. Immune cells that have taken up the vaccine nanoparticles release into circulation large numbers of exosomes containing spike protein along with critical microRNAs that induce a signaling response in recipient cells at distant sites. We also identify potential profound disturbances in regulatory control of protein synthesis and cancer surveillance. These disturbances potentially have a causal link to neurodegenerative disease, myocarditis, immune thrombocytopenia, Bell’s palsy, liver disease, impaired adaptive immunity, impaired DNA damage response and tumorigenesis. We show evidence from the VAERS database supporting our hypothesis. We believe a comprehensive risk/benefit assessment of the mRNA vaccines questions them as positive contributors to public health.


  1. Abe M., Bonini N.M. MicroRNAs and neurodegeneration: role and impact. Trends Cell Biol. 2013;23(1):30–36. doi: 10.1016/j.tcb.2012.08.013. – DOI – PMC – PubMed
  2. Agashe D., Martinez-Gomez N.C., Drummond D.A., Marx C.J. Good codons, bad transcript: large reductions in gene expression and fitness arising from synonymous mutations in a key enzyme. Mol. Biol. Evol. 2013;30:549–560. doi: 10.1093/molbev/mss273. – DOI – PMC – PubMed
  3. Akiyama H., Kakiuchi S., Rikitake J., Matsuba H., Sekinada D., Kozuki Y., Iwata N. Immune thrombocytopenia associated with Pfizer-BioNTech’s BNT162b2 mRNA COVID-19 vaccine. IDCases. 2021;25 doi: 10.1016/j.idcr.2021.e01245. – DOI – PMC – PubMed
  4. Al-Khalaf H.H., Aboussekhra A. p16 controls p53 protein expression through miR-dependent destabilization of MDM2. Mol. Cancer Res. 2018;16(8):1299–1308. doi: 10.1158/1541-7786.MCR-18-0017. – DOI – PubMed
  5. Alsamman K., El-Masry O.S. Interferon regulatory factor 1 inactivation in human cancer. Biosci. Rep. 2018;38(3) doi: 10.1042/BSR20171672. 2018. – DOI – PMC – PubMed

Leave a Reply

Your email address will not be published. Required fields are marked *